Ascendis Pharma A/S (ASND)
NASDAQ
226.05
-1.98 (-0.87%)
Closed
Oct 6, 2026
Day's Range
222.72230.91
52 wk Range
186.05282.15
Financial Statements - ASND - Ascendis Pharma A/S
Revenue
720.13M▲ 66.5%
Net Income
-228.03M▲ 49.3%Net Margin -31.7%
EBITDA
-66.49M▲ 78.1%
Free Cash Flow
45.41M▲ 112.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 720.13M | 432.59M | 266.71M | 51.17M | 7.77M | 6.95M |
| Cost of Goods | 94.91M | 52.64M | 44.39M | 12.13M | 3.52M | 0 |
| Gross Profit | 625.21M | 379.94M | 222.32M | 39.03M | 4.25M | 6.95M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -136.27M | -331.61M | -455.54M | -561.81M | -451.79M | -330.62M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -31.50M | -64.93M | 8.60M | 7.25M | 71.06M | -88.44M |
| Pre Tax Income | -212.65M | -444.01M | -474.14M | -577.81M | -383.94M | -419.17M |
| Income Tax | 15.38M | 5.76M | 7.30M | 5.37M | -367K | -219K |
| Net Income | -228.03M | -449.77M | -481.44M | -583.19M | -383.57M | -418.95M |
| EPS Basic | -3.76 | -6.53 | -8.55 | -10.4 | -7 | -8.28 |
| EPS Diluted | -3.76 | -6.53 | -8.55 | -10.4 | -7 | -8.28 |
| Basic Shares Outstanding | 60.60M | 68.86M | 53.95M | 54.10M | 52.85M | 48.84M |
| Diluted Shares Outstanding | 60.60M | 68.86M | 53.95M | 54.10M | 52.85M | 48.84M |
| Ebit | -132M | -366.08M | -430.07M | -547.13M | -380.03M | -417.25M |
| Ebitda | -66.49M | -303.94M | -438.16M | -554.12M | -423.66M | -328.88M |
| Net Income Continuous Operations | -228.03M | -449.77M | -481.44M | -583.19M | -383.57M | -418.95M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
